Kestra Advisory Services LLC Trims Position in Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Posted by on Apr 19th, 2023

Kestra Advisory Services LLC cut its holdings in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) by 52.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 31,963 shares of the biopharmaceutical company’s stock after selling 34,654 shares during the quarter. Kestra Advisory Services LLC’s holdings in Horizon Therapeutics Public were worth $3,637,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the business. Advisors Asset Management Inc. increased its holdings in shares of Horizon Therapeutics Public by 17.2% during the 3rd quarter. Advisors Asset Management Inc. now owns 3,244 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 477 shares in the last quarter. Bank of Montreal Can increased its holdings in shares of Horizon Therapeutics Public by 1.5% during the 3rd quarter. Bank of Montreal Can now owns 859,802 shares of the biopharmaceutical company’s stock valued at $55,044,000 after purchasing an additional 12,724 shares in the last quarter. Crossmark Global Holdings Inc. purchased a new position in shares of Horizon Therapeutics Public during the 4th quarter valued at approximately $209,000. Calton & Associates Inc. purchased a new position in shares of Horizon Therapeutics Public during the 4th quarter valued at approximately $208,000. Finally, Strs Ohio increased its holdings in Horizon Therapeutics Public by 0.8% in the 3rd quarter. Strs Ohio now owns 715,500 shares of the biopharmaceutical company’s stock worth $44,282,000 after acquiring an additional 5,994 shares in the last quarter. 91.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, StockNews.com initiated coverage on shares of Horizon Therapeutics Public in a report on Wednesday. They issued a “buy” rating for the company. Eight equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $111.42.

Horizon Therapeutics Public Price Performance

Horizon Therapeutics Public stock opened at $111.90 on Wednesday. Horizon Therapeutics Public Limited has a 52-week low of $57.84 and a 52-week high of $117.49. The firm has a market capitalization of $25.56 billion, a price-to-earnings ratio of 50.18, a PEG ratio of 4.20 and a beta of 1.13. The company has a fifty day simple moving average of $109.58 and a 200-day simple moving average of $98.10. The company has a quick ratio of 3.67, a current ratio of 3.85 and a debt-to-equity ratio of 0.50.

Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) last released its earnings results on Wednesday, March 1st. The biopharmaceutical company reported $1.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.09 by $0.12. Horizon Therapeutics Public had a net margin of 14.37% and a return on equity of 23.04%. The business had revenue of $942.03 million during the quarter, compared to analyst estimates of $922.95 million. During the same quarter in the prior year, the firm earned $1.41 earnings per share. The company’s revenue for the quarter was down 7.1% compared to the same quarter last year. On average, equities analysts anticipate that Horizon Therapeutics Public Limited will post 5.31 EPS for the current fiscal year.

Horizon Therapeutics Public Company Profile

(Get Rating)

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS.

Featured Articles

Institutional Ownership by Quarter for Horizon Therapeutics Public (NASDAQ:HZNP)

Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.